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Eradication of Helicobacter pylori Infection in Patients with Non-Ulcer 
Dyspepsia
Effects on Basal and Bombesin-Stimulated Serum Gastrin and Gastric Acid Secretion
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Verhuist ML, Hopman WPM, Tangerman A, Jansen JBMJ. Eradication of Helicobacter pylori infection 
in patients with non-ulcer dyspepsia. Effects on basal and bombesin-stimulated serum gastrin and gastric 
acid secretion. Scand J Gastroenterol 1995;30:968-973.
Background: This study evaluates the effect of eradicating Helicobacter pylori on basal and bombesin- 
stimulated gastric acid secretion and serum gastrin in non-ulcer dyspepsia. Methods: Before and 1 month 
after an attempt to eradicate H. pylori basal and bombesin-stimulated gastric acid outputs were measured 
in 23 patients. H. pylori was eradicated in 15 patients (group A) but not in the other 8 (group B). 
Incremental gastric acid output was calculated by subtracting basal from bombesin-stimulated values. 
Results: Basal acid output increased significantly (p = 0.01) after therapy in group A (A l.6 ± 0 .6  
mmol/h) but not in group B (A0.2 ± 0*5 mmol/ll). Incremental gastric acid output decreased distinctly 
(A -3 .9  ± 1.4mmol/h) after therapy in group A (p = 0.02) but not in group B ( A - 2.2 ± 1.7mmol/h). 
Basal serum gastrin decreased significantly (p < 0,005) after therapy in group A ( A - 9  ± 4pM) but not in 
group B ( A - l  ± 2 pM). Integrated serum gastrin responses to bombesin decreased markedly (p < 0.001) 
after therapy in group A  ( A - 5 .0 ±  1.6nM*60min) but slightly in group B (A -0 .9  + 1.3nM*60min) 
(p < 0*05). Conclusions: In patients with non-ulcer dyspepsia basal serum gastrin concentrations decrease 
but basal gastric acid outputs increase after eradication of H, pylori. Bombesin-induced increments in 
gastric acid output, however, decrease in parallel with gastrin release.
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Infection with Helicobacter pylori is now recognized as the 
main factor in the pathogenesis of duodenal ulcer disease and 
is strongly associated with an increased risk of gastric 
carcinoma (1,2), H . pylori predominantly colonizes the 
antral mucosa, where it causes chronic, diffuse, superficial 
gastritis (3,4). After eradication of the organism, gastritis and 
duodenal ulcer recurrence disappear (3-5). Infection with H. 
pylori also increases serum gastrin concentrations (6,7). It 
has been shown that//, pylori-related hypergastrinemia is the 
result of a selective increase of gastrin-17 (8), a molecular 
form that is almost exclusively released from the antrum (9). 
This raises the possibility that hypergastrinemia due to H. 
pylori infection is responsible for the abnormalities of gastric 
acid secretion which have been described in patients with 
duodenal ulcers (10). However, despite a reduction of serum 
gastrin after eradication of H  pylori, no consistent changes in 
gastric acid secretion have been reported (10-14).
Absence of a parallel reduction of circulating gastrin levels 
and gastric secretion after eradication of H. pylori has been 
attributed to the hypothesis that H. pylori decreases parietal 
cell sensitivity to gastrin (15), but other studies do not support 
this hypothesis (16-18). Studies on the effect of eradicating
H. pylori on gastric acid secretion and gastrin release have 
mainly focused on duodenal ulcer patients (6-8,12,13,18, 
19) or have compared H  pylori-positive volunteers with 
H, pylori-negative subjects (11,14,20,21). To elucidate 
the effect of H. pylori on gastric acid secretion and gastrin 
release in non-ulcer dyspepsia, we have measured basal and 
stimulated gastric acid secretion and serum gastrin concen­
trations before and 1 month after eradication therapy for 
ƒƒ. pylori . For this purpose we have stimulated gastric acid 
secretion by infusion of bombesin. This peptide selectively 
releases gastrin from the antrum (22), which is the main 
location affected by H. pylori infection (3,4). Bombesin- 
stimulated gastrin release is, unlike meal-stimulated 
gastrin release, not sensitive to luminal factors such as 
pH (7). Furthermore, intravenous stimulation avoids the 
technical difficulties encountered in the measurement of 
gastric acid secretion by meal stimulation. To try to exclude 
possible interference of anti-//, pylori drugs with gastrin 
release and gastric acid secretion, we have used two different 
treatment regimens to eradicate H  pylori and have studied 
patients before and 1 month after discontinuation of medical 
therapy.
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Twenty-five H . pylori-positive patients (8 women, 17 men; 
mean age, 42 ± 8 years) with upper abdominal complaints 
without a history of peptic ulcer disease or previous surgery 
were studied. Reflux esophagitis and gastric or duodenal ulcer 
disease were excluded by endoscopy. In all patients medica-
PATIENTS AND METHODS spectrophotometrically. The data were used to calculate 
recoveries of gastric juice (23).
After correction for recoveries, basal gastric acid output 
(BAO) was calculated by summation of the four 15-min 
samples before infusion of bombesin and expressed in 
mmol/h. Stimulated gastric acid output was calculated by
tion was stopped at least 10 days before the study. None of the sl” tion of a11 f™ r samPles Musion of
patients had used proton pump inhibitors. H. pylori infection bombesin after correction for recovery. Incremental gastric
was confirmed in all patients by histologic examination of ac^  ou|Put was calculated by subtracting BAO from bom-
antral biopsy specimens, by rapid urease test (CLO test) on besin-stimulated gastric acid output. These values are also
antral specimens, and by culture of antral specimens. All expressed in mmol/h.
these showed H . pylori in the patients selected for this study.
To define a normal range for bombesin-stimulated gastric
acid secretion, we have also included a group o f nine H. gastrin-17 coupled with n-(3-dimethylaminopropyl-)-JV'-
pylori-negative healthy control subjects (six women, three ethyl-carbodiimide hydrochloride to bovine serum albumin.
men; mean age, 26 ± 5 years).
Gastrin was measured by radioimmunoassay (24). The 
antiserum used was raised in a rabbit to non-sulfated human
Secretory studies
After a 12-h fast all patients and healthy subjects reported 
to the gastrointestinal research laboratory at 0830 h, Two 
indwelling intravenous catheters were placed, one in each 
forearm. One of these catheters was used for collection of 
blood samples and was kept patent with a heparin-saline 
solution, whereas the other was used for infusion of 
bombesin. For this purpose, synthetic bombesin (UCB, 
Brussels, Belgium) was dissolved in saline containing 2% 
human albumin under aseptic conditions and stored at -2 0  °C 
in aliquots of 3 nmol/ml. An orogastric drainage tube with 
multiple side holes and a metallic tip at the end was 
swallowed. The patient was then positioned on the left side 
in a bed. A small-bore perfusor tube (NPBI b.v. Emmer 
Compascuum, The Netherlands) was inserted into one of the 
side holes of the drainage tube. After the position of the 
drainage tube had been checked by means of the water 
recovery test (23), the perfusor tube was pulled back 10 cm to 
disconnect this tube from the drainage tube. After the stomach 
was emptied, 200 ml/15 min saline with phenol red (23) as a 
recovery marker was perfused through the perfusion tube 
during the entire study period. Intermittent suction was ap­
plied to the drainage tube, using an intermittent suction unit 
(Medela median, Hoek-Loos, The Netherlands) that applies 
suction for 60 sec in each 120-sec suction cycle. After an 
equilibration period of 30 min four 15-min collections were 
obtained under basal conditions followed by four 15-min 
collections during intravenous infusion of 90pmol/kg*h of 
bombesin. After each 15-min collection period one blood 
sample was drawn for measurement of gastrin, and the serum 
was stored at -2 0  °C.
The volume of the aspirates was recorded, and the 
concentration of H+ was measured in the samples by titration 
to pH 7,0 with 0.17V NaOH, using an autotitrator (ETS 822, 
Radiometer, Copenhagen). Aliquots for phenol red measure­
ment in the perfusates and aspirates were taken and 
centrifuged. Phenol red concentrations were determined
The antibody binds to the COOH-terminal bioactive site of 
sulfated and non-sulfated gastrins and binds gastrin-17 and 
gastrin-34 with almost equal affinity. Cross-reaction with 
structurally related (cholecystokinin (CCK)) and unrelated 
peptides was negligible. The intra-assay variation was below 
10% in the working range of the standard curve. All serum 
samples were measured in one run.
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Fig. 1. Basal serum gastrin levels (pM) before and after therapy in 
patients in whom Helicobacter pylori eradication treatment was 
successful (upper panel) or in whom eradication of H. pylori had 
failed (lower panel).
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The basal serum gastrin value for each patient was 
determined by taking the mean of the two serum gastrin 
concentrations obtained before the start of bombesin infusion. 
Integrated serum gastrin responses to bombesin were 
calculated by the trapezoidal rule after subtraction of basal 
values (25) and expressed as nM*60min.
Eradication o f H. pylori
After the gastric acid secretion studies, H. /Ty/on-positive 
patients were treated either with 120 mg bismuth subcitrate 
four times daily (n - 14) or 1 g sucralfate four times daily 
[n = 11) for 4 weeks. During the last 10 days of the treatment 
course all patients also used 500 mg metronidazole three 
times daily and 500 mg amoxicillin three times daily. One 
month after completion of this treatment the endoscopy was 
repeated, and antral biopsy specimens were taken for 
histologic examination, for the CLO test, and for culture. 
The secretory studies were also repeated at this point, in 
accordance with the same protocol. The study protocol was 
approved by the local ethical committee of the University 
Hospital, Nijmegen, and all patients gave their informed 
consent.
Statistical analysis
Statistical analysis of paired data was done with the 
Wilcoxon test and of unpaired data with the Mann-Whitney 
U test. Differences with a two-tailed probability (p) value of 
less than 0.05 were considered significant.
RESULTS
Two patients refused to participate in the gastric acid 
secretion study 1 month after therapy and were excluded 
from the study.
Histologic examination of antral biopsy specimens, CLO 
tests, and cultures of antral tissue 1 month after completion of 
triple therapy showed that#, pylori had been eradicated in 15 
of the remaining 23 non-ulcer dyspeptic patients (group A), 
whereas in the other 8 patients K  pylori infection persisted 
(group B), No significant differences in H . pylori eradication 
rates were observed between the two treatment regimens.
Basal serum gastrin concentrations before triple therapy 
were 33 ± 5 pM in group A and 22 ± 2pM in group B. These 
values were not significantly different from each other 
(0.05 < p  < 0.10). One month after triple therapy basal serum
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Fig. 2. Basal gastric acid secretion (mmol/h) before and after 
therapy in patients in whom Helicobacter pylori eradication 
treatment was successful (upper panel) or in whom eradication of 
H. pylori had failed (lower panel).
Before After
Fig. 3. Bombesin-stimulated serum gastrin concentration time 
curves (pM*60min) before and after therapy in patients in whom 
Helicobacter pylori eradication treatment was successful (upper 
panel) or in whom eradication of H. pylori had failed (lower panel).
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gastrin concentrations were markedly lower than before 
therapy (24 ± 4 pM) in the group-A patients (p < 0.005) but 
remained at the same level as before therapy (21 ± 2pM) in 
the group-B patients (Fig. 1).
The BAO before therapy in group A was 4.3 ± 1.1 mmol/h 
and in group B 6.0 ± 2.2 mmol/h. These values were not 
significantly different from each other (0.40 < p  < 0.50). One 
month after triple therapy BAO was markedly higher = 
0.01) than before therapy in group A (5.9 ± 1.0 mmol/h) 
but remained at the same level as before therapy in group B 
(6,2 ± 1.8 mmol/h) (Fig. 2).
The gastrin responses to bombesin for the patients in 
groups A and B, before and 1 month after therapy, are 
depicted in Fig. 3. Integrated serum gastrin responses to 
bombesin in group A and group B before therapy were
8.3 ± 1.9 nM*60 min and 5.8 ± 1.4 nM*60 min, respectively. 
These values were not significantly different from each other. 
One month after triple therapy integrated serum gastrin 
responses to bombesin had decreased significantly to 3.2 ± 
L3nM *60m in (p < 0.001) in group A and to 4.9 ± 1.3 nM* 
60 min in group B (p < 0,05). The decrease in integrated 
serum gastrin responses to bombesin in group A was signifi­
cantly greater than in group B (p < 0.01).
Bombesin markedly stimulated gastric acid output (p  < 
0.01). Bombesin-stimulated gastric acid output before triple 
therapy was 12.5 ±2.1 mmol/h in the group-A patients and
15.3 ± 2.5 mmol/h in the group-B patients. These values were 
not significantly different from each other. One month after 
triple therapy bombesin-stimulated gastric acid secretion was 
10.1 ± 1.6mmoI/h in group A and 13.2 ± 1 .4mmol/h in group 
B. Neither in group A nor in group B was the bombesin- 
stimulated gastric acid response significantly different from 
pre-treatment values (Fig. 4), However, after subtraction of 
basal gastric acid responses from bombesin-stimulated gastric 
acid responses in group A, post-treatment values (4.3 ± 0.9 
mmol/h) were significantly (p < 0.01) lower than pre-treat- 
ment values (8.3 ± 1.5 mmol/h), whereas in group B post­
treatment values (7.0 ± 1.4 mmol/h) were not significantly 
different from pre-treatment values (9.3 ± 2.0 mmol/h) (Fig, 
5). In the healthy H, /?y/m-negative volunteers delta gastric 
acid responses to bombesin (3.8 ± 2.0 mmol/h) were not sig­
nificantly different from corresponding values after success­
ful eradication of H . pylori in the patients of group A  (4.3 ± 
0.9 mmol/h).
Before therapy the ratio of incremental gastric acid and 
integrated gastrin response to bombesin in group A (1.6 ± 0.3)
Before After
Fig. 4. Bombesin-stimulated gastric acid secretion (mmol/h) before 
and after therapy in patients in whom Helicobacter pylori 
eradication treatment was successful (upper panel) or in whom 
eradication of H . pylori had failed (lower panel).
Fig. 5. Incremental bombesin-stimulated gastric acid secretion 
(mmol/h) before and after therapy in patients in whom Helicobacter 
pylori eradication treatment was successful (upper panel) or in 
whom eradication of H . pylori had failed (lower panel).
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was not significantly different from the ratio in group B 
(1.8 ± 0.4). After therapy this ratio increased markedly by 
190 ± 80% (p  < 0,05) in the patients of group A but not in 
those of group B (20% ± 30%).
DISCUSSION
This study shows that basal gastric acid output slightly 
increases after eradication of H. pylori in patients with non- 
ulcer dyspepsia, notwithstanding a distinct decrease of serum 
gastrin concentrations. These findings were not expected, 
since gastrin is a powerful stimulus of gastric acid secretion 
and since previous studies have shown that basal gastric acid 
secretion was either unaffected or decreased in parallel with 
basal serum gastrin levels after eradication of H . pylori in 
duodenal ulcer patients (10-14). However, our findings are in 
line with a recent uncontrolled study showing that basal 
gastric acid output in H. pylori-positive normal subjects is 
significantly lower than basal gastric acid output in H. pylori- 
negative controls and duodenal ulcer patients (26).
These are several studies indicating that infection with H. 
pylori may decrease gastric acid secretion. It has been shown 
in vivo that acute infection with H. pylori causes hypo- 
chloihydria (27) and that chronic infection is inversely 
correlated with gastric acid secretion (20,28), whereas in 
vitro H. pylori also inhibits gastric acid secretion, suggesting 
that H. pylori produces a gastric acid-inhibiting factor (29) or 
lowers gastric histamine levels (30). In addition, in previous 
studies no or a negative correlation was found between basal 
serum gastrin levels and basal gastric acid output (31—33), 
suggesting that a decrease of basal serum gastrin levels must 
not inevitably be accompanied by a decrease of basal gastric 
acid output.
Differences in the effect of eradication of H. pylori on basal 
gastric acid secretion between non-ulcer dyspepsia patients 
and duodenal ulcer patients may also be explained otherwise, 
since previous studies have found differences in sensitivity of 
parietal cells for gastrin between patients with and without 
duodenal ulcer (14—17) or differences in cholinergic activity 
(34). Furthermore, a fall in basal acid secretion in duodenal 
ulcer patients may not necessarily be due to the eradication of
H. pylori, since Achord (35) has shown that basal acid output 
decreases after healing of an ulcer by drugs that do not 
eradicate H. pylori, implying that the ulcer itself is associated 
with increased basal acid secretion. Finally, extension of if. 
pylori infection into the gastric body in patients with non­
ulcer dyspepsia, but not in duodenal ulcer disease, may be 
another possibility for explaining differences in basal gastric 
acid secretion between these patient groups.
Notwithstanding a higher basal gastric acid output in 
duodenal ulcer patients when compared to H . /?>>/ori-positive 
controls (26), basal gastric acid output varies considerably 
among H . pylori-po&itive, duodenal ulcer patients (20). 
Previous studies on gastric acid secretion in such patients 
were mainly performed in individuals with high BAOs
(10,12). These duodenal ulcer patients may respond differ­
ently after eradication of H. pylori. Nevertheless, in our series
4 of 15 non-ulcer dyspeptic patients had BAOs exceeding
5 mmol H+/h, and 2 of these 4 patients secreted even more 
than 10 mmol H+/h under basal conditions, but no consistent 
decrease of BAO was found in these patients after eradication 
of H. pylori. Therefore, high BAOs by themselves are 
probably not responsible for the difference in responses to 
successful H. pylori eradication therapy by duodenal ulcer 
patients and H . pylori-positive patients with non-ulcer 
dyspepsia.
Stimulation with bombesin resulted in comparable gastric 
acid outputs before and 1 month after eradication of H. pylori, 
despite a marked decrease of the serum gastrin response 1 
month after eradication of K  pylori when compared with 
before triple therapy. At first glance these data suggest that 
gastrin release and gastric acid secretion are also independent 
from each other under stimulated conditions. However, after 
subtraction of gastrin-independent basal gastric acid secre­
tion, incremental gastric acid secretion in response to 
bombesin significantly decreased 1 month after successful 
eradication of H, pylori to values comparable to those found 
in healthy H . pylori-negative control subjects. The data 
therefore suggest that stimulated but not basal gastric acid 
secretion is regulated by gastrin and that the decrease of 
gastrin release after successful eradication of H. pylori is in 
fact responsible for the significantly lower stimulated 
incremental gastric acid output when compared with before 
triple therapy. In the patients in whom eradication of H. pylori 
was not successful a small but significant decrease of 
bombesin-stimulated gastrin was also observed. This may 
indicate that H. pylori was suppressed but not eradicated in 
these patients and that a reduced bacterial load resulted in the 
observed decrease of gastrin release. It is of interest that the 
ratio of incremental gastric acid and integrated gastrin 
response to bombesin increased significantly after eradication 
of H . pylori. This finding is compatible with the hypothesis 
that eradication of H. pylori increases parietal sensitivity to 
gastrin or increases the number of parietal cells, thereby 
augmenting the gastric acid response to endogenous gastrin.
In conclusion, the present data demonstrate that in patients 
with non-ulcer dyspepsia basal gastric acid secretion 
increases after eradication of H. pylori despite a decrease of 
basal serum gastrin concentrations. Stimulated gastric acid 
secretion, however, decreases in parallel with gastrin release, 
suggesting that the decrease of stimulated gastric acid 
secretion but not basal gastric acid secretion is mediated by 
gastrin.
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